Company profile
Oxford Mestar | Home Page
Oxford MEStar is a rapidly growing, energetic company specialising in translational and regenerative medicine whilst strengthening connections with China.
Updated 07 Jul 2026 09:49
Financial period: 1 Nov 2023 to 31 Oct 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Oxford MEStar develops techniques for the transportation and preservation of living tissue and stem cell therapies, focusing on transferring these techniques to the Chinese market.
R&D service for biopharmaceutical, biotech and biomedical industry.
Employed 12 full time employee. Attracted £2.1M investment from overseas.
1 Feb 2018 to 31 Jan 2020
Recent advances in cell therapy and immunotherapy are changing the face of modern medicine. In particular a new type of treatment – CAR-T therapy – made from the patient’s own immune cells is offering new hope to cancer sufferers. The drawback of these treatments is that they are extraordinarily expensive to produce using current methods and hence are una...
1 Feb 2018 to 30 Nov 2018
"Recent advances in cell therapy and immunotherapy are changing the face of modern medicine. In particular a new type of treatment -- CAR-T therapy, made from the patient's own immune cells -- is offering new hope to cancer patients. The drawback of these treatments is that they are extraordinarily expensive to produce using current methods and hence are ...
1 May 2017 to 31 Jul 2019
Implants that can help osteoarthritis patients to repair damaged or diseased cartilage have had limited success to date and are only available to repair small areas of cartilage damage. University College London has invented a novel biomimetic osteochondral scaffold that replicates the properties of natural cartilage and can be shaped to fit the joint mor...
